Anti-&agr;4 integrin therapy for multiple sclerosis: Mechanisms and rationale

  title={Anti-\&agr;4 integrin therapy for multiple sclerosis: Mechanisms and rationale},
  author={George P. Rice and H. P. Hartung and Peter A. Calabresi},
The symptoms, severity, and course of multiple sclerosis (MS) vary among patients, leading to complex treatment issues. In recent years, research has focused on specific adhesion molecules that participate in the activation and function of lymphocytes, especially the migration of these cells to sites of inflammation. In particular, the integrin, very late activation antigen (VLA)-4, has been implicated in mediating adhesion and migration of immune cells through interaction with its ligand… 

Adhesion Molecule Profile and the Effect of Anti-VLA-4 mAb Treatment in Experimental Autoimmune Encephalomyelitis, a Mouse Model of Multiple Sclerosis

The therapeutic mechanism of anti-VLA-4 mAb treatment seems to include a complex influence on a variety of adhesion molecules expressed by infiltrating cells and vascular endothelium, including ICAM-1 and LFA-1 which exhibited the highest expression levels in the peak phase of EAE.

Integrin-directed antibody-based immunotherapy: focus on VLA-4

Blocking the interaction between VLA-6 integrin and laminin, experimentally abrogates heart graft rejection and suggests the development of smaller and more specific antibody reagents should be envisioned as a next-generation promising strategy.

Modulation of Experimental Autoimmune Encephalomyelitis by VLA‐2 Blockade

Data suggest that blocking cell–ECM interactions can be an alternative therapy for MS, and uses an antibody against the integrin α2, VLA‐2, that interacts with ECM, not vascular endothelium.

An Update on Monoclonal Antibody Therapies in Multiple Sclerosis

The role of mAbs in the treatment of MS is reviewed, particularly their advantages over other drugs and their limitations, which have to be overcome for these agents to be at the forefront in the Treatment of MS.

Drug Insight: using monoclonal antibodies to treat multiple sclerosis

The state of development of various therapeutic mAbs for MS treatment is reviewed, including natalizumab (Tysabri®), a mAb against α4 integrin, which was very effective in suppressing MS activity, but had to be withdrawn from the market because several treated patients developed progressive multifocal leukoencephalopathy.

Cytokine Signaling in Multiple Sclerosis and Its Therapeutic Applications

An overview on cytokines that may contribute to the pathogenesis of MS or EAE is presented, and successful examples and roadblock of translating data obtained from EAE to MS are provided, and the potential of targeting effector myeloid cells as a treatment strategy for MS is discussed.

Modulation of dendritic cell development by immunoglobulin G in control subjects and multiple sclerosis patients

The possibility that IgG treatment, apart from its known ability to regulate inflammation, may help to prevent relapses of MS by controlling DC maturation is suggested, consequently inhibiting invasion of immune cells into the central nervous system and affecting the cytokine profile.

Targeting the B7 Family of Co-Stimulatory Molecules

The expression of both stimulatory and inhibitory B7 molecules seems to play an essential role in modulating immune cell function through a variety of mechanisms, which is supported by findings that suggest each B7 molecule has developed its own indispensable niche in the immune system.

Monoclonal antibody therapy in multiple sclerosis

The appearance of progressive multifocal leukoencephalopathy (PML) in natalizumab-treated MS patients, as well as in patients with lymphoma, lupus and rheumatoid arthritis treated with rituximab, and autoimmune-type complications in alemtuzumab - treated MS patients underlines the fact that extended efficacy comes with significant clinical risks.

Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid

This is the first study to show that natalizumab treatment is associated with a global decline in cytokine and chemokine levels at a protein level, and this finding was most pronounced in CSF, in line with the reduced transmigration of cells into CNS, whereas reduction in plasma levels indicates other possible mechanisms of natalizer treatment.



Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis.

Mouse monoclonal antibodies directed against human alpha 4 integrin were analyzed in vitro for their ability to block the interaction of leukocytes with VCAM-1 under different assay conditions and AN100226, a humanized antibody, was as effective as AN 100226m in the reversal of active EAE in guinea pigs and thus may be useful in the treatment of autoimmune diseases such as multiple sclerosis.

Beta7 integrins contribute to demyelinating disease of the central nervous system.

It is shown that an antibody directed against the beta7 subunit greatly attenuates a non-remitting form of EAE, induced by adoptive transfer of myelin oligodendrocyte peptide (MOG35-55)-stimulated T cells.

Beneficial effect of modified peptide inhibitor of α4 integrins on experimental allergic encephalomyelitis in Lewis rats

Results show that small‐molecule inhibitors of α4 integrins act therapeutically in EAE possibly by interfering with cell adhesion events involved in this autoimmune disease.

Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin

In vitro adhesion assay on tissue sections found that lymphocytes and monocytes bound selectively to inflamed EAE brain vessels, and therapies designed to interfere with α4βl integrin may be useful in treating inflammatory diseases of the central nervous system, such as multiple sclerosis.

Prevention of a chronic progressive form of experimental autoimmune encephalomyelitis by an antibody against mucosal addressin cell adhesion molecule‐1, given early in the course of disease progression

It is shown that an antibody directed against MAdCAM‐1, the preferential ligand for α4β7, effectively prevented the development of a progressive, non‐remitting, form of EAE, actively induced by injection of myelin oligodendrocyte glycoprotein peptide (MOG35–55) autoantigen.

Blockade of signaling via the very late antigen (VLA-4) and its counterligand vascular cell adhesion molecule-1 (VCAM-1) causes increased T cell apoptosis in experimental autoimmune neuritis

The early increase of T cell apoptosis following disruption of VLA-4/VCAM-1 interaction may reflect a novel signaling component of proapoptotic pathways.

The Dale E. McFarlin memorial lecture: The immunology of the multiple sclerosis lesion

No single immune system molecule can be assigned as unusual to the CNS in MS, and while there appears to be nothing unique about the manner in which the CNS responds to the inflammation, the true uniqueness of the situation in MS is probably related to the many, normally sequestered, specific antigens within the myelin sheath and the biology of the myelinating cell, the oligodendrocyte.

Migration of T Cells in Vivo: Molecular Mechanisms and Clinical Implications

The migration of labeled T-cell subsets in unmanipulated animals is reviewed to demonstrate that preferential tissue accumulation of T- cell subsets can be due to increased local proliferation and a reduced rate of programmed cell death (apoptosis), and the relevance of these findings to the clinical outcome of anti-adhesion-molecule therapy.

A controlled trial of natalizumab for relapsing multiple sclerosis.

In a placebo-controlled trial, treatment with natalizumab led to fewer inflammatory brain lesions and fewer relapses over a six-month period in patients with relapsing multiple sclerosis.